Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties

This publication has 22 references indexed in Scilit:

• Adjunctive brivaracetam for refractory partial-onset seizures
  Neurology, 2010
• Benefit of combination therapy in epilepsy: A review of the preclinical evidence with levetiracetam
  Epilepsia, 2009
• Initial Management of Epilepsy
  New England Journal of Medicine, 2008
• SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy
  Neuropharmacology, 2008
• Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model
  Neurology, 2007
• Conformational Change in an MFS Protein: MD Simulations of LacY
  Structure, 2007
• Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein
  European Journal of Pharmacology, 2006
• Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain
  European Journal of Pharmacology, 2003
• SV2, a Brain Synaptic Vesicle Protein Homologous to Bacterial Transporters
  Science, 1992
• Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
  Biochemical Pharmacology, 1973